Skip to main content

35 - References

References

Prescribing in children and adolescents CHAPTER 5 References

  1. National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE Guideline [NG87]. 2018 (last updated September 2019, last accessed December 2023); https://www.nice.org.uk/guidance/NG87.
  2. Carucci S, et al. Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-­ analysis. Neurosci Biobehav Rev 2021; 120:­509–­525.
  3. Biederman J, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-­release in children with ADHD: a double-­blind, placebo-­controlled, crossover analog classroom study. Biol Psychiatry 2007; 62:­970–­976.
  4. Coghill D, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-­deficit/ hyperactivity disorder. Eur Neuropsychopharmacol 2013; 23:­1208–­1218.
  5. Findling RL, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-­deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011; 50:­395–­405.
  6. Heal DJ, et al. Amphetamine, past and ­present –­ a pharmacological and clinical perspective. J Psychopharmacol 2013; 27:­479–­496.
  7. Coghill DR, et al. Long-­term safety and efficacy of lisdexamfetamine dimesylate in children and adolescents with ADHD: a phase IV, 2-­year, open-­label study in Europe. CNS Drugs 2017; 31:­625–­638.
  8. Joseph A, et al. Comparative efficacy and safety of attention-­deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. Eur Child Adolesc Psychiatry 2017; 26:­875–­897.
  9. Cortese S, et al. Comparative efficacy and tolerability of medications for attention-­deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-­analysis. Lancet Psychiatry 2018; 5:­727–­738.
  10. Findling RL, et  al. Long-­term effectiveness and safety of lisdexamfetamine dimesylate in school-­aged children with attention-­deficit/­ hyperactivity disorder. CNS Spectr 2008; 13:­614–­620.
  11. Childress AC, et al. Efficacy and safety of lisdexamfetamine in preschool children with attention-­deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2022; 61:­1423–­1434.
  12. Michelson D, et al. Once-­daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a ­randomized, placebo-­controlled study. Am J Psychiatry 2002; 159:­1896–­1901.
  13. Kratochvil CJ, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-­label trial. J Am Acad Child Adolesc Psychiatry 2002; 41:­776–­784.
  14. Weiss M, et al. A randomized, placebo-­controlled study of once-­daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005; 44:­647–­655.
  15. Kratochvil CJ, et al. A double-­blind, placebo-­controlled study of atomoxetine in young children with ADHD. Pediatrics 2011; 127:­e862–­e868.
  16. Catala-­Lopez F, et al. The pharmacological and non-­pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-­analyses of randomised trials. PLoS One 2017; 12:e0180355.
  17. Liu Q, et al. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-­deficit hyperactivity disorder in children and adolescents: meta-­analysis based on head-­to-­head trials. J Clin Exp Neuropsychol 2017; 39:­854–­865.
  18. Yu S, et al. Guanfacine for the treatment of attention-­deficit hyperactivity disorder: an updated systematic review and meta-­analysis. J Child Adolesc Psychopharmacol 2023; 33:­40–­50.
  19. Radonjicˊ NV, et al. Nonstimulant medications for attention-­deficit/hyperactivity disorder (ADHD) in adults: systematic review and meta-­ analysis. CNS Drugs 2023; 37:­381–­397.
  20. Connor DF, et al. A meta-­analysis of clonidine for symptoms of attention-­deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999; 38:­1551–­1559.
  21. Hazell P. Tricyclic antidepressants in children: is there a rationale for use? CNS Drugs 1996; 5:­233–­239.
  22. Otasowie J, et  al. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 2014; 9:CD006997.
  23. Gorman DA, et al. Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-­deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder. Can J Psychiatry 2015; 60:­62–­76.
  24. Ng QX. A systematic review of the use of bupropion for attention-­deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol 2017; 27:­112–­116.
  25. Biederman J, et al. A comparison of once-­daily and divided doses of modafinil in children with attention-­deficit/hyperactivity disorder: a randomized, double-­blind, and placebo-­controlled study. J Clin Psychiatry 2006; 67:­727–­735.
  26. Wang SM, et al. Modafinil for the treatment of attention-­deficit/hyperactivity disorder: a meta-­analysis. J Psychiatr Res 2017; 84:­292–­300.
  27. Nasser A, et al. A phase III, randomized, double-­blind, placebo-­controlled trial assessing the efficacy and safety of viloxazine extended-­release capsules in adults with attention-­deficit/hyperactivity disorder. CNS Drugs 2022; 36:­897–­915.
  28. Einarson TR, et al. Novel Antipsychotics for Patients with Attention-­Deficit Hyperactivity Disorder: a Systematic Review. Technology Report No. 17. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2001.
  29. Pringsheim T, et al. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-­deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-­analysis. Part 2: antipsychotics and traditional mood stabilizers. Can J Psychiatry 2015; 60:­52–­61.
  30. Ji N, et  al. An update on pharmacotherapy for autism spectrum disorder in children and adolescents. Curr Opin Psychiatry 2015; 28:­91–­101.
  31. Pozzi M, et al. Emerging drugs for the treatment of attention-­deficit hyperactivity disorder (ADHD). Expert Opin Emerg Drugs 2020; 25:­395–­407.
  32. Humphreys KL, et al. Stimulant medication and substance use outcomes: a meta-­analysis. JAMA Psychiatry 2013; 70:­740–­749.

604 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 5 33. Treuer T, et al. A systematic review of combination therapy with stimulants and atomoxetine for attention-­deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability. J Child Adolesc Psychopharmacol 2013; 23:­179–­193. 34. McCracken JT, et al. Combined stimulant and guanfacine administration in attention-­deficit/hyperactivity disorder: a controlled, comparative study. J Am Acad Child Adolesc Psychiatry 2016; 55:­657–­666.e651. 35. Zhang L, et al. Risk of cardiovascular diseases associated with medications used in attention-­deficit/hyperactivity disorder: a systematic review and meta-­analysis. JAMA Network Open 2022; 5:e2243597. 36. Zhang L, et al. Attention-­deficit/hyperactivity disorder medications and long-­term risk of cardiovascular diseases. JAMA Psychiatry 2024; 81:­178–­187. 37. Wolraich ML, et al. Pharmacokinetic considerations in the treatment of attention-­deficit hyperactivity disorder with methylphenidate. CNS Drugs 2004; 18:­243–­250. 38. Joint Formulary Committee. British National Formulary (online). London: BMJ and Pharmaceutical Press; http://www.medicinescomplete.com. 39. Janssen-­Cilag Ltd. Summary of product characteristics. Concerta XL 18mg, 27mg, 36mg and 54mg prolonged-­release tablets. 2023; https://www.medicines.org.uk/emc/product/6872/smpc. 40. Efron D, et al. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-­blind, crossover trial. Pediatrics 1997; 100:­662–­666. 41. Hennissen L, et al. Cardiovascular effects of stimulant and non-­stimulant medication for children and adolescents with ADHD: a systematic review and meta-­analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS Drugs 2017; 31:­199–­215. 42. Gadow KD, et al. Efficacy of methylphenidate for attention-­deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry 1995; 52:­444–­455. 43. Cohen SC, et al. Meta-­analysis: risk of tics associated with psychostimulant use in randomized, placebo-­controlled trials. J Am Acad Child Adolesc Psychiatry 2015; 54:­728–­736. 44. Hoare P, et al. 12-­month efficacy and safety of OROS MPH in children and adolescents with attention-­deficit/hyperactivity disorder switched from MPH. Eur Child Adolesc Psychiatry 2005; 14:­305–­309. 45. Remschmidt H, et al. Symptom control in children and adolescents with attention-­deficit/hyperactivity disorder on switching from immediate-­ release MPH to OROS MPH. Results of a 3-­week open-­label study. Eur Child Adolesc Psychiatry 2005; 14:­297–­304. 46. Wolraich ML, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-­deficit/hyperactivity disorder. Pediatrics 2001; 108:­883–­892. 47. Findling RL, et al. Comparison of the clinical efficacy of twice-­daily Ritalin and once-­daily Equasym XL with placebo in children with attention deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry 2006; 15:­450–­459. 48. Anderson VR, et al. Spotlight on methylphenidate controlled-­delivery capsules (Equasym XLTM) in the treatment of children and adolescents with attention-­deficit hyperactivity disorder. CNS Drugs 2007; 21:­173–­175. 49. Flynn Pharma Ltd. Summary of product characteristics. Medikinet XL 5mg, 10mg, 20mg, 30mg, 40mg, 50mg and 60mg modified release capsules (methylphenidate hydrochloride). 2023; https://www.medicines.org.uk/emc/product/313/smpc. 50. Medicines and Healthcare products Regulatory Agency. Public assessment report. Ritalin XL 10mg, 20mg, 30mg, 40mg, 60mg modified-­ release hard capsules (last updated March 2014); https://mhraproductsproduction.blob.core.windows.net/docs/4781baf366b1fafd0ea20396 2ccb54faadcdcfcc. 51. Cyr M, et al. Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder. Drugs 1998; 56:­215–­223. 52. Takeda UK Ltd. Summary of product characteristics. Elvanse 20mg, 30mg, 40mg, 50mg, 60mg and 70mg capsules, hard (lisdexafetamine). 2023; https://www.medicines.org.uk/emc/product/14091/smpc. 53. Kelsey DK, et al. Once-­daily atomoxetine treatment for children with attention-­deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-­blind, placebo-­controlled trial. Pediatrics 2004; 114:­e1–­e8. 54. Wernicke JF, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26:­729–­740. 55. Heil SH, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 2002; 67:­149–­156. 56. Reed VA, et al. The safety of atomoxetine for the treatment of children and adolescents with attention-­deficit/hyperactivity disorder: a comprehensive review of over a decade of research. CNS Drugs 2016; 30:­603–­628. 57. Childress A, et al. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents. Expert Opin Pharmacother 2020; 21:­417–­426. 58. Takeda UK Ltd. Guanfacine modified-­release. Personal communication, 2020. 59. Cortese S, et al. New formulations of methylphenidate for the treatment of attention-­deficit/hyperactivity disorder: pharmacokinetics, efficacy, and tolerability. CNS Drugs 2017; 31:­149–­160.

No comments to display

Back to top